Alligator reveals positive data for pancreatic cancer drug

Alligator Bioscience shared positive results from its Phase Ib/II OPTIMIZE-1 trial (NCT04888312) for mitazalimab, a monoclonal antibody therapy targeting pancreatic cancer.

Presented at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) and published in Lancet Oncology on June 3, the Phase II data revealed promising outcomes. Patients receiving mitazalimab alongside mFOLFIRINOX showed a 40.4% objective response rate (ORR) and a median overall survival (mOS) of 14.3 months. This outperforms historical mFOLFIRINOX results, where the typical ORR was 31.6%, with mOS of 11.1 months.

In February 2024, the FDA approved Ipsen Biopharmaceuticals’ NALIRIFOX, a chemotherapy combination for first-line pancreatic cancer treatment. Combining Onivyde with oxaliplatin, fluorouracil, and leucovorin, NALIRIFOX marks the second FDA-approved Onivyde regimen for metastatic pancreatic adenocarcinoma.

Mitazalimab, a CD40 agonist, enhances immune response by activating memory T cells, offering potential in pancreatic cancer treatment.